739 Emerging proteomic and safety analysis of blood from solid tumor patients receiving TILT-123 (Ad5/3-E2F-d24-hTNFa-IRES-hIL2) monotherapy in TUNIMO phase 1 clinical trial

• Tuomo Alanko,
• Akseli Hemminki,
• Víctor Cervera-Carrascón,
• João Santos,
• Riikka Havunen,
• Juha Kononen,
• Jorma Sormunen,
• Katriina Peltola,
• Riitta Korpisaari,
• Marjut Jaakkola,
• Suvi Sorsa,
• Santeri A Pakola,
• James Clubb,
• Elise Jirovec,
• Dafne CA Quixabeira,
• Tatiana Kudling,
• Lyna Haybout,
• Claudia Kistler

Affiliations

Tuomo Alanko

4Docrates Cancer Center, Helsinki, Finland

Akseli Hemminki

2Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland

Víctor Cervera-Carrascón

1Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland

João Santos

1Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland

Riikka Havunen

1Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland

Juha Kononen

4Docrates Cancer Center, Helsinki, Finland

Jorma Sormunen

4Docrates Cancer Center, Helsinki, Finland

Katriina Peltola

3Comprehensive Cancer Centre, Helsinki, Finland

Riitta Korpisaari

4Docrates Cancer Center, Helsinki, Finland

Marjut Jaakkola

4Docrates Cancer Center, Helsinki, Finland

Suvi Sorsa

2TILT Biotherapeutics Ltd, Helsinki, Finland

Santeri A Pakola

2Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland

James Clubb

3TILT Biotherapeutics, Helsinki, Finland

Elise Jirovec

2Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland

Dafne CA Quixabeira

1Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland

Tatiana Kudling

2Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland

Lyna Haybout

2Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland

Claudia Kistler

2TILT Biotherapeutics Ltd, Helsinki, Finland